About Boxer Capital
Boxer Capital is a vehicle for Tavistock Life Science's investment in a portfolio of public companies and private equity crossover opportunities. Boxer Capital leverages its internal expertise in evaluating pre-clinical and clinical data to generate outsized returns for company founders and employees as well for its investor the Tavistock Group. Boxer Capital has a focus on biotechnology drug development companies across multiple therapeutic indications.
Boxer Capital Headquarter Location
P.O. Box 9000
Windermere, Florida, 34786,
Latest Boxer Capital News
Jan 19, 2022
Ceptur Therapeutics, Inc. (“Ceptur”), a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, today announced the completion of a $75M Series A financing. The round was co-led by venBio Partners and Qiming Venture Partners USA with participation by new investors Perceptive Xontogeny Venture (PXV) Fund, Bristol Myers Squibb and Janus Henderson Investors along with existing Seed investors Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. The post Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology appeared first on BioBuzz.
Boxer Capital Team
5 Team Members
Boxer Capital has 5 team members, including current Senior Vice President, Dominik Naczynski.